US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at -0.49 against a street estimate of 0.70 — a miss of 170.0%.
Analysts rate Liquidia Technologies Inc a buy (9 buy, 0 hold, 1 sell out of 10) with an average price target of $107.75.
| Fund | Stake |
|---|---|
| Farallon Capital Management, L.L.C. | 9.67% |
| Caligan Partners LP | 9.07% |
| BlackRock Inc | 6.13% |
| Findell Capital Management LLC | 3.91% |
| Vanguard Capital Management, LLC | 3.27% |
| Opaleye Management Inc | 2.73% |
| Bank of America Corp | 2.56% |
| Geode Capital Management, LLC | 2.16% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 LIQUIDIA CORPORATION – FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Liquidia Corporation (ticker: LQDA, Nasdaq-listed) • Report date: September 3, 2 | 2026-09-03 |
| Quarterly report · Q2 2026 LIQUIDIA CORPORATION - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and cash equivalents: $284.2 million as of Jun | 2026-08-12 |
| Results announced · Q3 2026 LIQUIDIA CORPORATION Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 YUTREPIA net product sales: $170.4 million, up 31% from Q1 2026 ($ | 2026-08-12 |
| Shareholder vote results · Q2 2026 LIQUIDIA CORPORATION (LQDA) - 8-K SUMMARY HEADLINE NUMBERS • Annual shareholder meeting held June 16, 2026 • 88,893,621 shares outstanding as of Apr | 2026-06-17 |
| Company announcement · Q2 2026 LIQUIDIA CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Liquidia Corporation (NASDAQ: LQDA) • Headquarters: 419 Davis Drive, Suite 100, | 2026-06-08 |
| Quarterly report · Q1 2026 LIQUIDIA CORPORATION – Q1 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash and Cash Equivalents: $222.8 million as of March 31, 2026 (up fr | 2026-05-11 |
| Proxy statement · Q2 2026 LIQUIDIA CORPORATION PROXY STATEMENT SUMMARY --- CEO COMPENSATION & CHANGES • Roger A. Jeffs, Ph.D. (CEO) total compensation: Not specified in prov | 2026-04-24 |
| Annual report FY2025 LIQUIDIA CORPORATION - ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Company: Liquidia Corporation (ticker: LQDA, Nasdaq), Delaware corporation, headquar | 2026-03-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Exclusive licensing agreement for treprostinil product development and commercialization Liquidia Corporation signed an exclusive licensing deal with Vectura Limited on October 27, 2025, to develop and sell treprostinil-based treatments in the U.S. market. The drug will be admin | 2025-10-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Liquidia Technologies Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.